These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 12500228

  • 1. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E, Ofsthun N, Lazarus JM.
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [Abstract] [Full Text] [Related]

  • 2. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [Abstract] [Full Text] [Related]

  • 3. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K, Moran J, Hlatky M, Lafayette R.
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [Abstract] [Full Text] [Related]

  • 4. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
    Spiegel DM, Khan I, Krishnan M, Mayne TJ.
    Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting anemia management in hemodialysis patients: a single-center experience.
    Spiegel DM, Gitlin M, Mayne T.
    Hemodial Int; 2008 Jul; 12(3):336-41. PubMed ID: 18638090
    [Abstract] [Full Text] [Related]

  • 6. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 7. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan KE, Lafayette RA, Whittemore AS, Hlatky MA, Moran J.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2948-56. PubMed ID: 18469314
    [Abstract] [Full Text] [Related]

  • 8. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 9. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK.
    Am J Kidney Dis; 2004 Jul; 44(1):94-111. PubMed ID: 15211443
    [Abstract] [Full Text] [Related]

  • 10. [Hemoglobin variability in patients with chronic renal insuffiency].
    Deray G.
    Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
    Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1087-95. PubMed ID: 15752888
    [Abstract] [Full Text] [Related]

  • 12. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
    Fishbane S.
    Blood Purif; 2007 Mar 15; 25(1):53-7. PubMed ID: 17170538
    [Abstract] [Full Text] [Related]

  • 13. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep 15; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 15; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 15. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
    Kessler M, Landais P, Canivet E, Yver L, Bataille P, Brillet G, Commenges B, Koné S.
    Nephrol Ther; 2009 Apr 15; 5(2):114-21. PubMed ID: 19042175
    [Abstract] [Full Text] [Related]

  • 16. Hemoglobin variability in epoetin-treated hemodialysis patients.
    Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB.
    Kidney Int; 2003 Oct 15; 64(4):1514-21. PubMed ID: 12969173
    [Abstract] [Full Text] [Related]

  • 17. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.
    Capelli JP, Kushner H.
    Hemodial Int; 2008 Oct 15; 12(4):450-62. PubMed ID: 19090868
    [Abstract] [Full Text] [Related]

  • 18. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS.
    Semin Dial; 2005 Oct 15; 18(1):22-9. PubMed ID: 15663760
    [Abstract] [Full Text] [Related]

  • 19. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.
    Ebben JP, Gilbertson DT, Foley RN, Collins AJ.
    Clin J Am Soc Nephrol; 2006 Nov 15; 1(6):1205-10. PubMed ID: 17699349
    [Abstract] [Full Text] [Related]

  • 20. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K.
    J Am Soc Nephrol; 2006 Apr 15; 17(4):1181-91. PubMed ID: 16565261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.